A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Improved Survival in Thrombotic Thrombocytopenic Purpura–Hemolytic Uremic Syndrome1991 · 867 citations
2. 2Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura2020 · 122 citations
3. 3Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura2018 · 165 citations
4. 4Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study2016 · 48 citations
5. 5Thrombotic thrombocytopenic purpura2017 · 714 citations